Jiangsu Mingde Pharmaceutical Co., Ltd., registered and established in February 2021, is located in the biotechnology park of Yangzhou national high tech Industrial Development Zone. It is a modern high-tech biopharmaceutical enterprise focusing on the R & D, production and sales of high-end preparations such as parenteral nutrition drug fat emulsion injection and drug loaded fat emulsion injection. With a registered capital of 200 million yuan and a planned total investment of 2 billion yuan, it covers an area of 123 mu.

The phase I construction project covers an area of about 80 mu. It plans and constructs high-end preparation production lines and supporting facilities of storage center according to the new GMP standards and FDA standards. After the project is completed, it can form an annual production capacity of 9 million bags (calculated as 250ml / bag) of fat emulsion high-volume injection and 45 million pieces (calculated as 20ml / piece) of drug loaded fat emulsion low-volume injection. The phase II construction project covers an area of about 44 mu. It is planned to build high-end preparation production projects such as pet medicine and biological vaccine preparation.

Focusing on scientific and technological innovation and R & D investment, the company has long maintained strategic cooperation with domestic well-known scientific research institutions such as Shanghai Pharmaceutical Industry Research Institute, China Pharmaceutical University, Nanjing University of technology, West China Medical College of Sichuan University, and the leading product production technology is at the forefront of China. In the future, the company's development goal is to strive to become a benchmark enterprise in the field of high-end complex preparations such as fat emulsion, liposome and microspheres.